Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Advocacy: 2020 Year in Review

Blair Solow, MD  |  January 11, 2021

Context: Step therapy is a burden for providers and patients. This legislation requires Employee Retirement Income Security Act (ERISA) health plans to allow for reasonable overrides for physicians to be able to use certain medications. The prior authorization legislation will protect patients in Medicare Advantage plans that delay or deny access to care. It also supports reporting back to the CMS how often Medicare Advantage plans approve or deny medications and services. Funding for DXA reimbursement is at an all-time low. This legislation will set a $98 floor for DXA reimbursement.

How you can help: With the 117th Congress, all bills will need re-introduction in 2021. Send a letter to Congress showing your support. Also, watch for calls to action to send letters to state legislators if you live in a state that has not passed step therapy reform.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Up Next
As we look ahead in 2021, the ACR government affairs team will be tackling several issues:

  1. Advocating for support for patients and providers during the remainder of the pandemic and monitoring any legislation and regulations that could affect provider and practice solvency;
  2. Protecting rheumatology evaluation and management payment increases;
  3. Engaging on policies related to telemedicine;
  4. Advancing legislation and regulations in the areas of:
    1. Prior authorization and other utilization management issues;
    2. Workforce;
    3. Telemedicine expansion and appropriate reimbursement; and
    4. NIH/DOD funding for rheumatology research;
  5. Engaging on drug pricing proposed policies and pilot programs and defending patient access to treatment;
  6. Addressing issues such as DXA and musculoskeletal ultrasound reimbursement; and
  7. Monitoring implementation of the new requirements related to surprise billing, including the rollout of the independent dispute resolution program through which payers and providers will negotiate reimbursement.

Thank you for your time, efforts, enthusiasm and perseverance. I look forward to an ongoing conversation about how advocacy and health policy affect you and your patients and how you can help. Join us for an advocacy event, we would love to see you!

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Wishing you and yours a Happy (and safe) New Year!


Blair Solow is chair of the ACR Government Affairs Committee and an assistant professor of medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center in Dallas.

Page: 1 2 3 | Single Page
Share: 

Filed under:American College of RheumatologyLegislation & Advocacy Tagged with:Blair SolowGovernment Affairs Committee (GAC)legislation and advocacy

Related Articles

    The ACR’s 2020 Advocacy Year in Review

    February 16, 2021

    To say it has been an interesting (the science and the memes), tumultuous (the politics) and heartbreaking (the pandemic and social injustice) year is an understatement. There have been moments of grace and inspiration that we hope have kept everyone going.  As we look to 2021, we take lessons from our experiences in 2020. Washington,…

    Telerheumatology: What’s Next?

    December 17, 2020

    In an ACR Convergence session, two rheumatologists discussed how COVID-19 changed the use of telemedicine, how payers reacted and which changes are likely permanent and which are likely to be temporary.

    Telehealth Brings Opportunities to Enhance Patient Care

    December 8, 2022

    During an ACR webinar in August, presenters discussed multiple aspects of telehealth in rheumatology, especially related to rheumatology fellowship training. They agreed that although telehealth represents one potential avenue to improve patient access to treatment for rheumatic disease, we must keep identifying the best ways to employ telehealth to enhance care. Impact of Pandemic Telemedicine…

    What’s Next for Telehealth after the COVID-19 Public Health Emergency?

    June 10, 2023

    Do you remember where you were when the COVID-19 Public Health Emergency (PHE) was declared on Jan. 31, 2020? While it may seem like yesterday, you would be forgiven for not recalling your exact location over three years ago during what felt like an incredible whirlwind for the healthcare industry. One possible location you may…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences